期刊
JOURNAL OF CLINICAL MEDICINE
卷 12, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/jcm12196428
关键词
autoantibodies; immunoadsorption; SF-36; physical function; long COVID; GPCR-antibodies; post-COVID syndrome; Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
There is increasing evidence suggesting an autoimmune cause for post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), with SARS-CoV-2 being the main trigger. A small proof-of-concept study on IgG depletion using immunoadsorption (IA) showed efficacy in most patients with post-infectious ME/CFS. An ongoing observational study aims to evaluate the efficacy of IA in post-COVID-19 ME/CFS patients.
There is increasing evidence for an autoimmune aetiology in post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). SARS-CoV-2 has now become the main trigger for ME/CFS. We have already conducted two small proof-of-concept studies on IgG depletion by immunoadsorption (IA) in post-infectious ME/CFS, which showed efficacy in most patients. This observational study aims to evaluate the efficacy of IA in patients with post-COVID-19 ME/CFS. The primary objective was to assess the improvement in functional ability. Due to the urgency of finding therapies for post-COVID-Syndrome (PCS), we report here the interim results of the first ten patients, with seven responders defined by an increase of between 10 and 35 points in the Short-Form 36 Physical Function (SF36-PF) at week four after IA. The results of this observational study will provide the basis for patient selection for a randomised controlled trial (RCT), including sham apheresis, and for an RCT combining IA with B-cell depletion therapy. Trial registration number: NCT05629988.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据